AD-35 is under clinical development by Zhejiang Hisun Pharmaceutical and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AD-35’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AD-35 is under development for the treatment of Alzheimer's disease. it is administered through the oral route as a tablet. It is a benzodioxole derivative and is a structurally modified compound of donepezil. It acts by targeting acetylcholinesterase (ACHE).
Zhejiang Hisun Pharmaceutical overview
Zhejiang Hisun Pharmaceutical (Hisun) manufactures and commercializes drugs to treat tumors, infections, cardiovascular, endocrine, depression and orthopedic disorders. The company’s product portfolio includes anti-tumor and anti-viral, hypoglycemic drugs, anti-infection drugs animal health products, anthelmintic, oral solid preparation drugs, weight loss pills, calcium supplements, immune suppressants, biological medicines and others. It provides medical information, product consultation and adverse drug reaction reports. Hisun operates research and development facilities in Shanghai and Beijing, China. The Company distributes its products in domestic markets and overseas markets. Hisun is headquartered in Taizhou, Zhejiang, China.
For a complete picture of AD-35’s drug-specific PTSR and LoA scores, buy the report here.